A Phase 1/2 Study of the Concomitant Administration of Indoximod Plus Immune Checkpoint Inhibitors for Adult Patients With Advanced or Metastatic Melanoma

Trial Profile

A Phase 1/2 Study of the Concomitant Administration of Indoximod Plus Immune Checkpoint Inhibitors for Adult Patients With Advanced or Metastatic Melanoma

Recruiting
Phase of Trial: Phase I/II

Latest Information Update: 04 May 2017

At a glance

  • Drugs Indoximod (Primary) ; Ipilimumab (Primary) ; Nivolumab (Primary) ; Pembrolizumab (Primary)
  • Indications Malignant melanoma
  • Focus Adverse reactions; Therapeutic Use
  • Sponsors NewLink Genetics Corporation
  • Most Recent Events

    • 04 May 2017 According to a NewLink Genetics Corporation media release, interim results of this trial were presented at the American Association for Cancer Research (AACR) 2017 Annual Meeting.
    • 04 Apr 2017 Interim results on a cohort of 60 patients who received indoximod plus pembrolizumab, published in a New Links Genetics Corporation Media Release.
    • 01 Mar 2017 Interim results of this trial will be presented at the American Association for Cancer Research (AACR) 2017 Annual Meeting, according to a NewLink Genetics Corporation media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top